Literature DB >> 19871486

BACTERIOSTATIC EFFECT OF HUMAN SERA ON GROUP A STREPTOCOCCI : II. COMPARATIVE BACTERIOSTATIC EFFECT OF NORMAL WHOLE BLOOD FROM DIFFERENT ANIMAL SPECIES IN THE PRESENCE OF HUMAN CONVALESCENT SERA.

S Rothbard1.   

Abstract

1. Heparin was more satisfactory for preventing blood from clotting than defibrination, potassium and ammonium oxalate, or sodium citrate in bacteriostasis of group A streptococci in the presence of streptococcal antibodies in convalescent serum. 2. Blood from rabbit, guinea pig, or sheep could not be substituted for human blood in promoting bacteriostasis when human antibody was used. Mixtures of human leukocytes and plasma of each of these animals or of animal leukocytes and human plasma were also not effective with human antibody. 3. Complement, leukocytes, and a thermostable factor which was found in human plasma were essential in the indirect bacteriostatic technique employed for the inhibition of streptococcal growth in the presence of convalescent human serum. 4. The thermostable component was active in human serum, as well as in plasma, in 1:12 dilution, withstood storage at 4 degrees C. for at least 7 weeks, and was destroyed by heating at 70 degrees C. for 30 minutes.

Entities:  

Year:  1945        PMID: 19871486      PMCID: PMC2135542          DOI: 10.1084/jem.82.2.107

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  5 in total

1.  THE OCCURRENCE OF BACTERIOSTATIC PROPERTIES IN THE BLOOD OF PATIENTS AFTER RECOVERY FROM STREPTOCOCCAL PHARYNGITIS.

Authors:  A G Kuttner; T F Lenert
Journal:  J Clin Invest       Date:  1944-03       Impact factor: 14.808

2.  AN ANALYSIS OF THE OPSONIC AND TROPIC ACTION OF NORMAL AND IMMUNE SERA BASED ON EXPERIMENTS WITH THE PNEUMOCOCCUS.

Authors:  H K Ward; J F Enders
Journal:  J Exp Med       Date:  1933-03-31       Impact factor: 14.307

3.  BACTERIOSTATIC EFFECT OF HUMAN SERA ON GROUP A STREPTOCOCCI : I. TYPE-SPECIFIC ANTIBODIES IN SERA OF PATIENTS CONVALESCING FROM GROUP A STREPTOCOCCAL PHARYNGITIS.

Authors:  S Rothbard
Journal:  J Exp Med       Date:  1945-08-01       Impact factor: 14.307

4.  BACTERIOSTATIC EFFECT OF HUMAN SERA ON GROUP A STREPTOCOCCI : III. INTERFERENCE WITH BACTERIOSTATIC ACTIVITY BY BLOCKAGE OF THE LEUKOCYTES.

Authors:  S Rothbard
Journal:  J Exp Med       Date:  1945-08-01       Impact factor: 14.307

5.  OBSERVATIONS ON THE PHAGOCYTOSIS OF THE PNEUMOCOCCUS BY HUMAN WHOLE BLOOD : I. THE NORMAL PHAGOCYTIC TITRE, AND THE ANTI-PHAGOCYTIC EFFECT OF THE SPECIFIC SOLUBLE SUBSTANCE.

Authors:  H K Ward
Journal:  J Exp Med       Date:  1930-04-30       Impact factor: 14.307

  5 in total
  6 in total

1.  Studies on the bacteriophages of hemolytic streptococci. II. Antigens released from the streptococcal cell wall by a phage-associated lysin.

Authors:  R M KRAUSE
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

2.  Immunity to the group B streptococci: interaction of serum and macrophages with types Ia, Ib, and Ic.

Authors:  B F Anthony
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

3.  Studies of phagocytosis of group A streptococci by polymorphonuclear leucocytes in vitro.

Authors:  J G HIRSCH; A B CHURCH
Journal:  J Exp Med       Date:  1960-03-01       Impact factor: 14.307

4.  Studies on the binding between streptococcal M protein and antibody.

Authors:  H M GREY
Journal:  J Exp Med       Date:  1962-03-01       Impact factor: 14.307

5.  Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci. I. A typical behavior of some human and rabbit bloods.

Authors:  G H STOLLERMAN; F S KANTOR; B D GORDON
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

6.  BACTERIOSTATIC EFFECT OF HUMAN SERA ON GROUP A STREPTOCOCCI : I. TYPE-SPECIFIC ANTIBODIES IN SERA OF PATIENTS CONVALESCING FROM GROUP A STREPTOCOCCAL PHARYNGITIS.

Authors:  S Rothbard
Journal:  J Exp Med       Date:  1945-08-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.